

16th January, 2026

BSE Limited

P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Intimation as per Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')

Board Meeting on Wednesday, 28th January, 2026

Dear Sir / Madam,

Pursuant to Regulation 29 of the SEBI Listing Regulations, we write to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday, 28th January, 2026, *inter alia* to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for quarter and nine months ended 31st December, 2025.

In this regard, we also write to inform you that the 'Trading Window' for dealing in the securities of the Company, which has been closed from Thursday, 1st January, 2026 will remain closed till Friday, 30th January, 2026 (both days inclusive).

Thanking you,

Yours truly,
For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India
T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

piramalpharma.com